A human antibody that blocks FSH to help Alzheimer's
A Humanized Monoclonal FSH Blocking Antibody for Alzheimer's Disease
This project is creating a human antibody that blocks a hormone called FSH to try to slow or prevent Alzheimer's disease in people.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11296517 on NIH RePORTER |
What this research studies
Researchers are turning a lab-made human antibody called Hu6 that blocks the hormone FSH into a medicine you could take for Alzheimer's. They have solved the antibody's structure, developed GLP-compliant labs, and made a stable formulation suitable for dosing in people. The team will finish preclinical safety, toxicity, and manufacturing studies in animals and lab tests to build an FDA IND application. If those steps succeed, the antibody could move into early human trials for people with early Alzheimer's or mild cognitive impairment.
Who could benefit from this research
Good fit: Future trials would likely enroll adults with early-stage Alzheimer's disease or mild cognitive impairment due to Alzheimer's pathology.
Not a fit: People with very advanced or non-Alzheimer's dementias are less likely to benefit from this therapy.
Why it matters
Potential benefit: If successful, this approach could provide a new treatment that slows neurodegeneration and cognitive decline in Alzheimer's disease.
How similar studies have performed: Targeting FSH is a novel approach with promising results in mouse models, but it has not yet been tested in people.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Zaidi, Mone — Icahn School of Medicine at Mount Sinai
- Study coordinator: Zaidi, Mone
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.